0001104659-22-002722.txt : 20220110 0001104659-22-002722.hdr.sgml : 20220110 20220110160748 ACCESSION NUMBER: 0001104659-22-002722 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220106 FILED AS OF DATE: 20220110 DATE AS OF CHANGE: 20220110 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Dierks Jeffrey CENTRAL INDEX KEY: 0001821102 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39450 FILM NUMBER: 22521342 MAIL ADDRESS: STREET 1: 630 W. GERMANTOWN PIKE STREET 2: SUITE 215 CITY: PLYMOUTH MEETING STATE: PA ZIP: 19462 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Harmony Biosciences Holdings, Inc. CENTRAL INDEX KEY: 0001802665 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 822279923 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 630 W GERMANTOWN PIKE STREET 2: SUITE 215 CITY: PLYMOUTH MEETING STATE: PA ZIP: 19462 BUSINESS PHONE: (484) 539-9800 MAIL ADDRESS: STREET 1: 630 W GERMANTOWN PIKE STREET 2: SUITE 215 CITY: PLYMOUTH MEETING STATE: PA ZIP: 19462 4 1 tm221863-2_4seq1.xml OWNERSHIP DOCUMENT X0306 4 2022-01-06 0 0001802665 Harmony Biosciences Holdings, Inc. HRMY 0001821102 Dierks Jeffrey 630 W. GERMANTOWN PIKE, SUITE 215 PLYMOUTH MEETING, PA 19462 1 1 0 0 Chief Commercial Officer Common Stock 2022-01-06 4 M 0 6125 8.22 A 6125 D Common Stock 2022-01-06 4 S 0 1399 39.5972 D 4726 D Common Stock 2022-01-06 4 S 0 4302 40.5345 D 424 D Common Stock 2022-01-06 4 S 0 424 41.2309 D 0 D Stock Option 8.22 2022-01-06 4 M 0 3690 0 D 2027-10-02 Common Stock 3690 9739 D Stock Option 8.22 2022-01-06 4 M 0 2435 0 D 2028-10-01 Common Stock 2435 4869 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.05 to $40.04. The reporting person undertakes to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.07 to $41.02. The reporting person undertakes to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $41.08 to $41.39. The reporting person undertakes to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The stock option is currently vested with respect to 0 shares, and will vest with respect to the remainder of the shares on October 1, 2022. The stock option is currently vested with respect to 0 shares, and will vest with respect to the remainder of the shares in two equal annual installments beginning on October 1, 2022. /s/ Christian Ulrich, Attorney-in-fact for Jeffrey Dierks 2022-01-10